$NIO Inc.(NIO)$    • Overbought setup: RSI near 80 is unsustainable. Even if earnings look “okay,” stocks often sell off after big pre-earnings runs. • Reality check: NIO is still burning cash. Losses last quarter were almost RMB 6.8B (~US$930M). A single “less bad” quarter won’t erase that. • Peer valuation: It’s trading like it’s already profitable, so any disappointment can hit harder. I'm shorting it now~ 

$Lululemon Athletica(LULU)$   Lululemon fell almost 18% in one day.  Big reasons: • They cut their full-year forecast again. • U.S. sales only grew 1%, which is weak. • Tariffs are hitting profits, costing them about $240M this year. • Analysts rushed to downgrade. Some even put price target at $150. That’s why the stock sank. But at today’s price, valuation looks much lower than before. If sales improve or holiday season is strong, it could bounce.

$Eli Lilly(LLY)$   Eli Lilly lost over $100 billion in one day. The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings. This is not just a bad day. It could be a shift in how investors value the company. Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story. Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.

$NIO Inc.(NIO)$   NIO’s run from ~$5.8 to ~$6.5 has been eye-catching, but the technicals are starting to look stretched. • RSI is above 88 → that’s extreme overbought. • Volume spike looks like FOMO rather than steady accumulation. • Support sits around $6.20 and then $6.00. A break could see quick downside. Yes, ES8 preorder buzz and Fed optimism gave it a lift, but history shows these rallies don’t run forever when the fundamentals (deliveries slowing, still unprofitable) haven’t changed. Isn’t anybody seeing this?

$NIO Inc.(NIO)$   NIO ran from $3 to almost $7 in just a few months. That shows the stock still has momentum power in the short term. Traders can play the swings. But long term, the story looks weak: • Still not profitable, keeps burning cash. • Competition in China EV market is too strong (BYD, Li Auto, Tesla). • Survival depends a lot on government support and subsidies. • Every time it rallies, sellers come in around $6–7. So short-term bulls may catch a bounce, but the bigger picture looks bearish to me. 🧸

$Tiger Brokers(TIGR)$  Revenue: $138.7M (+58.7% YoY) • Net Income: $41M–44M (up 8×–16× YoY) • Client Assets: $52.1B (+36% YoY, $3B net inflows this quarter) • Trading Volume: $284B (+168% YoY) • Funded Users: 1.19M (+21% YoY) This isn’t just “growth”, this is acceleration on all fronts: more clients, more money flowing in, more trades. They’re scaling fast and turning it into real profits. Yes, price pulled back today (classic “sell the news”), but the fundamentals are screaming strength. If momentum picks up again, TIGR has room to retest that $13+ zone and beyond. Markets love to overreact short term… but the numbers don’t lie. 

$Grab Holdings(GRAB)$   Grab just posted strong Q2 numbers and the trend looks good: • Revenue hit US$819M, up 23% YoY • Adjusted EBITDA jumped to US$109M (+69% YoY) • Deliveries up 23%, Financial Services up 41% • Sitting on a massive US$7.6B cash pile for growth + stability At today’s price around US$5.5-5.9, analysts still see upside to US$6-6.2+. With mobility, food delivery, and digital banking all under one super-app, Grab has a huge Southeast Asia market to grow into. Yes, competition is real, but profitability is improving and cash flow is getting stronger. I see this as a long-term compounder with room to run~~~~~~

$Tesla Motors(TSLA)$   Tesla had a strong push earlier in the day, climbing to around $345, before cooling off and dipping back toward $338. For me, this does not means "breakout failed” and instead feels like the market taking a breath before deciding on the next move. Why I still lean bullish: • Normal in big moves: Strong stocks often make a run, then shake out traders with a quick pullback. This flushes out weak hands and gives institutions a chance to reload. • Macro backdrop still friendly: Yesterday’s cooler inflation numbers have given growth stocks breathing room. The Fed may not be as aggressive, which usually works in Tesla’s favor. • Tesla’s unique attention cycle: When TSLA moves, it is not just pri

$Tesla Motors(TSLA)$   Tesla broke out above $367 earlier this month and has already run around $395. But fundamentals don’t match this rally: • Global EV sales growth slowed to +15% YoY in August, weakest since early 2024. • China EV sales up only +6%, Tesla’s China deliveries actually down ~10% YoY. • U.S. market share fell to ~38%, lowest in 8 years. • Forward P/E is stretched at ~140× 2026 earnings. Yes, AI, robotaxi, and energy are the future story. But for now, the auto business is cooling fast. To me this looks more like a short-term pop than the start of a new run. Short-term bearish~~~

$Synopsys(SNPS)$   SNPS crashed ~35% in a day after earnings, its one of its worst sell-offs. Earnings/revenue missed (EPS $3.39 vs $3.80 est, rev $1.74B vs $1.77B est), IP sales fell ~8% from export rules and customer issues, and guidance got cut. That’s why we saw the panic. But here’s the thing: even after the cut, full-year EPS is still $12.8. At today’s price, SNPS trades around 34–36× P/E, near its 3-yr average (~38×). For a company dominating chip design + AI software, that doesn’t look expensive. Analysts trimmed targets but still see $525–$600+ ahead. Long term, demand for chips and AI tools isn’t slowing and Synopsys is in the middle of it. Right now, I see $420 as strong support, but even here the up

$Novo-Nordisk A/S(NVO)$   Novo Nordisk just kept a worldwide asset freeze in place against KBP Biosciences and its founder while a New York arbitration decides if KBP hid trial quirks in a drug Novo bought. This is protective, not a final win. Stock impact is neutral to slightly positive for NVO. The facts: • A Singapore court granted and then upheld a global freezing order on KBP and Dr Huang. Purpose is to stop assets from moving while the case proceeds. • Novo alleges the antihypertensive drug showed an outlier effect at a Bulgarian site that was not seen elsewhere and says KBP failed to disclose that analysis to Novo. • KBP denies wrongdoing and says efficacy appeared at sites worldwide. • Merits go to intern

$Apple(AAPL)$   Apple just added over $400 billion in market cap in a single week, its best run since 2020. Why? A blowout quarter: $94B revenue (+10%), $1.57 EPS (+12%), iPhone sales +13%, Services at all-time highs. And they’re putting $100B into U.S. manufacturing, a move very few companies can afford. Even at a $3T valuation, the growth engine isn’t slowing. AI? That’s still untapped upside. One serious move there and the narrative explodes again.

$Novo-Nordisk A/S(NVO)$   Saw a post here with a pretty cautious take on Novo Nordisk (NVO). Figured I’d throw in my perspective. Yes, the stock is down about 42% this year. Earnings weren’t mind-blowing. There’s a CEO change. A lot of people are sitting on the sidelines. But here’s the thing. The company isn’t broken. The price is. You’re looking at a global pharma leader with: • Dominance in GLP-1 (Ozempic, Wegovy) • ROE over 80 percent • PE around 13 after the drop • Consistent revenue growth and strong free cash flow • Dividend stability and no debt red flags Some are saying the valuation doesn’t reassure them. That’s a price-driven reaction, not a fundamentals-based one. Fair enough if you’re a technical tra

$Tiger Brokers(TIGR)$  Price pulled back from ~$13.55 highs to around $10 now, that’s a ~25% correction after a big run-up. Profit-taking is normal, but here’s why I think this sets up well for a rebound trade: • Valuation: P/E is around 14–15× (down from ~18× earlier). Cheaper now compared to fintech peers. • Technical: RSI sitting mid-50s → not overbought, not oversold, giving room to bounce. • Support: $10 is a strong psychological + chart support. If it holds, upside could push to $11.50–12.00 near term. • Catalysts: Retail volumes can come back quick, and TIGR adding new features (AI assistant, better margin tools) keeps the platform sticky. Of course, if $10 fails, watch out for $9.80/$9 support. But risk/reward looks solid: riskin

$Fortinet(FTNT)$   Fortinet just took a heavy hit, dropping over 3% in a single day. This is after a brutal slide from its 52-week high of $114.82. The stock now sits around $72.89, flirting with its 52-week low of $67.98. What happened? The cybersecurity giant delivered results that could not live up to the lofty expectations baked into its price. Forward guidance came in soft and investors are questioning whether Fortinet can sustain its growth pace in a competitive, fast-evolving market. At a P/E near 29 and a P/B over 27, the valuation is still not “cheap” by any stretch. This means the market was pricing in near-flawless execution and the latest earnings call just cracked that perfection narrative. Yes, For

$NIO Inc.(NIO)$   I’m calling it bearish near term. Here’s why: • That $1B share offering? Classic dilution play. How many times can you keep milking shareholders before trust runs out? • Deliveries in Q2 hit 72k (+25% YoY), but revenue only rose 9%. Growth is already lagging behind the hype. • Gross margin at 10% is embarrassing compared to Tesla (18%) and BYD (20%+). Vehicle margin even declined vs last year — proof the EV price war is crushing them. • Net loss was still ~US$700M in Q2. With losses like that, “profitability” sounds like a fairytale. • Sure, they’ve got US$3.8B in cash, but at this burn rate they’ll be back for more handouts soon. The stock keeps choking in the $6–7 range, and unless bulls pull

$Novo-Nordisk A/S(NVO)$  Novo Nordisk just took a hit after earnings. Down but definitely not out. Market panicked over “weak guidance”, but let’s be real: this is the kingpin of obesity and diabetes treatment. Wegovy and Ozempic aren’t just drugs, they’re global megatrends in a syringe. • Massive R&D pipeline • Strong cash flow • Expanding globally • Current dip? Discounted entry. $NVO will make a comeback. 

$Fortinet(FTNT)$   Fortinet dropped after earnings even though they beat on EPS and revenue. The reason? Management said the firewall upgrade cycle is already 40–50% done, and analysts worry growth will slow from here. A bunch of downgrades followed, pushing the stock down hard. Bear view: growth from firewalls may be peaking, valuation still not cheap, and short-term price action looks weak. Bull view: fundamentals are strong, cybersecurity is a secular growth story, and analyst targets still range up to $126 (+50% upside). Near term it may chop around $75–85. But if you’re looking beyond a few quarters, this could be a chance to load up while sentiment is low.

$Amazon.com(AMZN)$   Two big catalysts just dropped: 1️⃣ Zoox driverless approval – HTSA has officially granted Amazon’s Zoox unit permission to operate fully driverless cars. This is a major milestone in autonomous transport and could put Amazon years ahead in integrating driverless tech into Prime delivery, AWS logistics and even ride-hailing. 2️⃣ Vehicle listings go live – Amazon has opened up vehicle listings to auto dealers. Think about the reach: millions of car buyers seeing inventory directly on Amazon’s platform. This could disrupt the traditional dealership model. If momentum continues, we could see a gap fill into the mid $220s and potentially retest the recent highs. Clear that level and we could see

$Intel(INTC)$   Intel just reported a flat revenue quarter and a small loss, but that is not the real story. The real headline is a company hit with painful yet necessary restructuring that is now facing a clean slate. Under new CEO Lip Bu Tan, Intel is slashing costs, shelving expensive fab projects, and trimming 15% of its workforce. This is corporate decluttering at a serious scale. The political spotlight is intense. Trump has publicly called for Tan’s resignation and the White House is involved. Intel now sits at the center of the U.S. chip sovereignty agenda. Billions in CHIPS Act funds are already flowing, which could be a catalyst for a stronger turnaround. Analysts are looking at a rebound to $22–$28, a